ESR1 and breast cancer: In ~ 20% of patients with metastatic BC, the endocrine treatment causes missense ESR1 mutations mainly at the Y537 and D538 residues of the LBD [3], which constitutively activate transcription without estrogen, resulting in the “constitutively active” phenotype that is insensitive to anti-estrogen drugs [3].